venBio Global Strategic Fund V, L.P.

Overview

• HeadquartersDE¹
• Legal formLimited Partnership
• Kind of organizationVenture capital fund¹

See how the biggest companies compare on our leaderboards

Corporate structure

venBio Global Strategic Fund V, L.P. sits at the top of its group. 3 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (2 companies). Each entity in the chart links to its source.

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerAaron Royston named Jul 12, 2024²
• Executive OfficerAntoinette Delhonte named Jul 12, 2024²
• Executive OfficerCorey Goodman named Jul 12, 2024²
• Executive OfficerDavid Pezeshki named Jul 12, 2024²
• Executive OfficerRichard Gaster named Jul 12, 2024²
• Executive OfficerYvonne Yamanaka named Jul 12, 2024²

Filings

1 filings to the SEC since October 2021: 1 private raises. The latest 1:

1. Jul 12, 2024D EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Stakes it holds

venBio Global Strategic Fund V, L.P. has told the SEC it owns more than 5% of 2 companies, latest first (Schedules 13D and 13G).

• Yarrow Bioscience, Inc.SCHEDULE 13G Aug 14, 2026³
• ACHIEVE LIFE SCIENCES, INC.SCHEDULE 13D Apr 27, 2026⁴

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Jun 28, 2024Raised $504.7 million in a private offering of securities² Form D: 162 investors so far Form D